[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2006114743A - Композиция корма для животных - Google Patents

Композиция корма для животных Download PDF

Info

Publication number
RU2006114743A
RU2006114743A RU2006114743/13A RU2006114743A RU2006114743A RU 2006114743 A RU2006114743 A RU 2006114743A RU 2006114743/13 A RU2006114743/13 A RU 2006114743/13A RU 2006114743 A RU2006114743 A RU 2006114743A RU 2006114743 A RU2006114743 A RU 2006114743A
Authority
RU
Russia
Prior art keywords
iaa
derivative
composition according
animal
feed composition
Prior art date
Application number
RU2006114743/13A
Other languages
English (en)
Other versions
RU2345552C2 (ru
Inventor
Юбер Жан Мари Франсуа ЖИЛЛЕССЕН (BE)
Юбер Жан Мари Франсуа ЖИЛЛЕССЕН
Кристиан РИБЬЕР (FR)
Кристиан РИБЬЕР
Original Assignee
Вейлен Н.В. (Nl)
Вейлен Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вейлен Н.В. (Nl), Вейлен Н.В. filed Critical Вейлен Н.В. (Nl)
Publication of RU2006114743A publication Critical patent/RU2006114743A/ru
Application granted granted Critical
Publication of RU2345552C2 publication Critical patent/RU2345552C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/168—Steroids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/184—Hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Insects & Arthropods (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Claims (18)

1. Композиция корма для животных, содержащая более 240 мкг свободной IAA (индолилуксусной кислоты) или ее производного на килограмм, в которой указанное производное выбирается из группы, состоящей из 4-гидрокси-IAA, 4-метокси-IAA, 5-гидрокси-IAA, 5-метокси-IAA, 6-гидрокси-IAA, 6-метокси-IAA, 7-гидрокси-IAA, 7-метокси-IAA и соединения, которое может превращаться в свободную IAA в 3, предпочтительно в 2 и более предпочтительно в 1 стадию.
2. Композиция корма по п.1, содержащая до 40 г свободной IAA или ее производного на килограмм.
3. Композиция корма по п.1, содержащая от 100 до 1000 мг свободной IAA или ее производного на килограмм.
4. Композиция корма по п.1, дополнительно содержащая фермент, способный превращать производное IAA в свободную IAA.
5. Композиция корма по п.4, содержащая ароматическое кольцо, в которой ароматическое кольцо в одном или более из 4, 5, 6 и 7 положений замещается метилом, амино, нитро, фторидом, хлоридом, бромидом или йодидом.
6. Композиция корма по любому из пп.1-5 в форме пеллетов, муки, зерен, экструдированных или воздушных зерен, таблеток, порошка или пилюль.
7. Способ увеличения скорости роста и/или улучшения эффективности корма и/или скорости конверсии корма и/или иммунитета животного, не относящегося к человеческому роду, включающий скармливание указанному животному эффективного количества композиции по любому из пп.1-6.
8. Применение свободной IAA или ее производного, в котором указанное производное выбирается из группы, состоящей из 4-гидрокси-IAA, 4-метокси-IAA, 5-гидрокси-IAA, 5-метокси-IAA, 6-гидрокси-IAA, 6-метокси-IAA, 7-гидрокси-IAA, 7-метокси-IAA и соединения, которое может превращаться в свободную IAA в 3, предпочтительно в 2 и более предпочтительно в 1 стадию, для приготовления лечебной композиции для стимуляции иммунной системы у животных, не относящихся к человеческому роду, при необходимости проведения такого лечения.
9. Применение по п.8, в котором свободная IAA или ее производное способны повысить уровень инсулиноподобного фактора роста 1 (IGF-1) в сыворотке крови.
10. Применение по п.8, в котором животное имеет пониженный уровень IGF-1.
11. Применение по любому из пп.8-10, в котором животные имеют дефицит роста и/или ослабленную иммунную систему.
12. Применение композиции по любому из пп.1-6 для приготовления лечебной композиции для стимуляции роста и/или стимуляции иммунной системы у животных при необходимости проведения такого лечения.
13. Применение по п.12, в котором свободная IAA или ее производное способны повысить уровень инсулиноподобного фактора роста 1 (IGF-1) в сыворотке крови.
14. Применение по п.12, в котором животное имеет пониженный уровень IGF-1.
15. Применение по любому из пп.12-14, в котором животные имеют дефицит роста и/или ослабленную иммунную систему.
16. Способ приготовления композиции корма для животного, включающий смешивание композиции по любому из пп.1-6 с одним или более веществом (-ами) или ингредиентом (-ами) корма для получения композиции корма для животного по любому из пп.1-6.
17. Способ приготовления композиции корма для животного, включающий стадию добавления в корм для животного свободной IAA или ее производного для получения композиции корма для животного по любому из пп.1-6.
18. Способ выращивания животных, не относящихся к человеческому роду, включающий а) смешивание эффективной дозы свободной IAA или ее производного с кормовым материалом с целью получения композиции корма по любому из пп.1-6, пригодной для конкретных видов животных, б) кормление указанных видов животных кормовым материалом.
RU2006114743/13A 2003-10-03 2004-09-28 Композиция корма для животных RU2345552C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP03/11171 2003-10-03
PCT/EP2003/011171 WO2005039546A2 (en) 2003-10-03 2003-10-03 Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases

Publications (2)

Publication Number Publication Date
RU2006114743A true RU2006114743A (ru) 2007-11-10
RU2345552C2 RU2345552C2 (ru) 2009-02-10

Family

ID=34429223

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006114743/13A RU2345552C2 (ru) 2003-10-03 2004-09-28 Композиция корма для животных

Country Status (16)

Country Link
US (2) US9408405B2 (ru)
EP (1) EP1670444B1 (ru)
JP (1) JP4641942B2 (ru)
CN (1) CN1938018B (ru)
AT (1) ATE506948T1 (ru)
AU (1) AU2003273967A1 (ru)
CA (1) CA2541090C (ru)
CY (1) CY1116665T1 (ru)
DE (1) DE60336934D1 (ru)
DK (1) DK1670444T3 (ru)
ES (2) ES2365847T3 (ru)
HK (1) HK1103963A1 (ru)
PT (2) PT1670444E (ru)
RU (1) RU2345552C2 (ru)
SI (1) SI1670444T1 (ru)
WO (1) WO2005039546A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10716778B2 (en) 2003-10-03 2020-07-21 Veijlen Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667678B1 (en) 2003-10-03 2009-05-06 Veijlen N.V. Animal feed composition
JPWO2005049006A1 (ja) * 2003-11-21 2007-11-29 味の素株式会社 糖尿病治療剤
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US9063122B2 (en) * 2008-10-17 2015-06-23 Alfredo Gallegos Biomodulators for treatment or prevention of disease
EP2440206B1 (en) * 2009-06-11 2018-07-18 DSM IP Assets B.V. Trigonellin as a muscle stimulant
US9790186B2 (en) 2009-07-21 2017-10-17 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104159595A (zh) 2012-02-15 2014-11-19 爱勒让治疗公司 拟肽大环化合物
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CA2896437C (en) * 2012-11-26 2021-01-19 Takaaki Abe Erythropoietin expression promoter
RU2524634C1 (ru) * 2013-06-25 2014-07-27 Государственное научное учреждение Северо-Кавказский зональный научно-исследовательский ветеринарный институт (ГНУ СКЗНИВИ) Российской академии сельскохозяйственных наук Способ стимуляции роста птицы
WO2015095650A1 (en) * 2013-12-19 2015-06-25 Puretein Bioscience Llc. Methods for treating an animal
KR102265412B1 (ko) * 2014-08-13 2021-06-14 주식회사 엘지생활건강 그라민 또는 이의 약학적으로 허용가능한 염을 포함하는 피부 미백, 탄력, 주름개선, 보습 또는 항염증용 화장료 또는 약학 조성물
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
CA2970539A1 (en) * 2014-12-16 2016-06-23 Puretein Bioscience Llc. Methods for increasing serum igf-1 in an animal
TWI588128B (zh) * 2015-01-13 2017-06-21 財團法人國家衛生研究院 5-甲氧基色胺酸及其衍生物及其用途
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017035288A1 (en) * 2015-08-27 2017-03-02 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US11701348B1 (en) 2016-07-23 2023-07-18 Turtle Bear Holdings, Llc Psilocybin compositions
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
MX2021007026A (es) * 2018-12-13 2021-10-22 Aim Immunotech Inc Metodos para mejorar la tolerancia al ejercicio en pacientes con encefalomielitis mialgica.
JP2022529476A (ja) 2019-04-17 2022-06-22 コンパス パスファインダー リミテッド 不安障害、頭痛障害、及び摂食障害をサイロシビンで治療するための方法
CN111407884B (zh) * 2019-06-24 2021-12-07 浙江大学 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途
CA3153776A1 (en) * 2019-09-09 2021-03-18 The University Of Chicago Combination therapy for the treatment of migraines
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス， インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
CA3158059A1 (en) 2019-11-19 2021-05-27 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
JP2023526856A (ja) 2020-05-19 2023-06-23 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
WO2022047580A1 (en) * 2020-09-01 2022-03-10 Magicmed Industries Inc. Hydroxylated psilocybin derivatives and methods of using
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2023130075A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified organisms for producing psychotropic alkaloids
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CN114870018A (zh) * 2022-05-12 2022-08-09 江南大学 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用
CN115813918B (zh) * 2022-09-30 2024-04-02 中国药科大学 吲哚乙酸在制备抑郁症治疗药物中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA957281A (en) * 1970-02-03 1974-11-05 Nathan N. Share Pharmaceutical compositions containing indole-3-acetic acid derivatives as a skeletal muscle stimulant
US4025650A (en) 1975-11-24 1977-05-24 Control Drug, Inc. Method and composition for preventing nutritional deficiency
GB1475861A (en) * 1976-03-19 1977-06-10 Warner Lambert Co Pharmaceutical composition
GB1535778A (en) * 1976-12-06 1978-12-13 Mac Sweeney D Compounds useful in treatment of unipolar depression
JPS60199801A (ja) 1984-03-24 1985-10-09 Masaki Kamata 動物に対する植物成長ホルモンの投与方法
US4687763A (en) * 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
BE1000990A3 (nl) 1987-10-09 1989-05-30 Picanol Nv Inrichting voor het op elkaar aansluiten van onderling verplaatsbare elementen, en transportinrichting die eerstgenoemde inrichting toepast.
GB8727099D0 (en) * 1987-11-19 1987-12-23 Cellena Cell Eng A G Compositions containing melantonin/homologues
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
IT1237472B (it) 1989-10-04 1993-06-07 Polifarma Spa Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico.
US5132113A (en) * 1990-10-26 1992-07-21 Maurizio Luca Nutritional composition containing essential amino acids
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
NZ244760A (en) * 1991-10-18 1997-02-24 Alza Corp Transdermal administration of melatonin; device comprising melatonin with skin permeation enhancer and melatonin impermeable backing on skin-distal device surface
GB9214419D0 (en) 1992-07-07 1992-08-19 Concannon Peter Biocidal agents
JPH0725838A (ja) * 1993-05-13 1995-01-27 Yotsuba Yuka Kk 疲労の予防または回復のための経口投与剤
JP3541969B2 (ja) 1994-09-29 2004-07-14 東洋紡績株式会社 ベットマット
JP3617102B2 (ja) 1995-01-27 2005-02-02 味の素株式会社 ヒト筋肉疲労の早期回復効果を有するアミノ酸栄養組成物
JPH08308580A (ja) * 1995-05-17 1996-11-26 Takeda Chem Ind Ltd 組換え型ヒトｇｈｒｈレセプター蛋白質、その製造法および用途
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
FR2741799B1 (fr) * 1995-12-04 1998-01-02 Oreal Utilisation de melatonine dans une composition pour traiter les signes cutanes des etats de fatigue
EP0873754B1 (en) * 1996-01-09 2003-07-30 Riken Amino acid compositions
FR2746313B1 (fr) * 1996-03-22 1998-04-17 Adir Utilisation de la melatonine et des ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention et au traitement du diabete et des complications diabetiques
US5958964A (en) * 1997-02-18 1999-09-28 South Alabama Medical Science Foundation Use of melatonin to prevent cytotoxic effects of amyloid beta protein
DE19739763A1 (de) * 1997-09-10 1999-09-23 Franz Uhl Vitamin B3/Niacin zur Behandlung von Krankheiten
US6017946A (en) * 1997-10-08 2000-01-25 Posner; Robert Serotonin containing formulation for oral administration and method of use
JP2002525265A (ja) * 1998-08-14 2002-08-13 アドミニストレイターズ オブ ザ トゥレーン エジュケーショナル ファウンド 成長ホルモン放出活性を有する化合物
BR9913457A (pt) 1998-09-03 2001-10-16 Neuronz Ltd Neuroproteção
IL132366A0 (en) 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
CN1069050C (zh) * 1998-12-01 2001-08-01 周旭生 一种治疗糖尿病的中药复方制剂
WO2000033834A1 (en) * 1998-12-04 2000-06-15 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
FR2795323B1 (fr) * 1999-06-23 2001-11-16 Adir Utilisation de ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention ou au traitement des pathologies du systeme gastrointestinal
CN1088597C (zh) * 1999-10-26 2002-08-07 合肥永生制药有限公司 尿多酸肽组合物及其用途
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
AU2001238718A1 (en) * 2000-03-02 2001-09-12 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
DE10037773C1 (de) * 2000-08-03 2002-08-22 Hennecke Gmbh Verfahren und Vorrichtung zum Herstellen von mit Langfasern verstärkten Kunststoff-Formteilen
DE10109798A1 (de) 2001-03-01 2002-09-12 Aventis Pharma Gmbh Gesundheitsfördernde Zusammensetzung von Verbindungen
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
JP2002281914A (ja) * 2001-03-27 2002-10-02 Nishi Nippon Green Kk 魚類、家畜類の栄養活力促進剤の製造方法
US20020147155A1 (en) * 2001-04-06 2002-10-10 Foster Warren G. Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands
CN1408397A (zh) * 2001-09-26 2003-04-09 北京本元青阳生物科技发展有限公司 含褪黑素和益智中药的组合物
JP2003137808A (ja) * 2001-10-26 2003-05-14 Kakunai Juyotai Kenkyusho:Kk 新規経腸栄養剤の製造法
JP2005522466A (ja) 2002-03-18 2005-07-28 ファルマシア・コーポレーション アルドステロン受容体アンタゴニスト、およびニコチン酸またはニコチン酸誘導体の組合わせ
CN1440744A (zh) * 2003-02-15 2003-09-10 高景曦 纳米包覆退黑激素复合保健品
WO2004098498A2 (en) 2003-04-28 2004-11-18 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
JP4641942B2 (ja) 2003-10-03 2011-03-02 フェーイレン・ナムローゼ・フェンノートシャップ ヒトおよび動物におけるｉｇｆ−１血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中ｉｇｆ−１レベルを増加できる化合物の使用
EP1667678B1 (en) 2003-10-03 2009-05-06 Veijlen N.V. Animal feed composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10716778B2 (en) 2003-10-03 2020-07-21 Veijlen Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals

Also Published As

Publication number Publication date
EP1670444B1 (en) 2011-04-27
US9408405B2 (en) 2016-08-09
WO2005039546A2 (en) 2005-05-06
WO2005039546A3 (en) 2007-10-04
CN1938018B (zh) 2010-09-01
AU2003273967A1 (en) 2005-05-11
SI1670444T1 (sl) 2011-09-30
CA2541090C (en) 2013-04-16
ES2326595T3 (es) 2009-10-15
CY1116665T1 (el) 2017-03-15
JP4641942B2 (ja) 2011-03-02
US20080194553A1 (en) 2008-08-14
US20160331725A1 (en) 2016-11-17
CA2541090A1 (en) 2005-05-06
RU2345552C2 (ru) 2009-02-10
ATE506948T1 (de) 2011-05-15
US10716778B2 (en) 2020-07-21
EP1670444A2 (en) 2006-06-21
ES2365847T3 (es) 2011-10-11
PT1670444E (pt) 2011-07-29
DE60336934D1 (de) 2011-06-09
JP2007525405A (ja) 2007-09-06
AU2003273967A8 (en) 2005-05-11
CN1938018A (zh) 2007-03-28
PT1667678E (pt) 2009-08-05
HK1103963A1 (en) 2008-01-04
DK1670444T3 (da) 2011-08-22

Similar Documents

Publication Publication Date Title
RU2006114743A (ru) Композиция корма для животных
CN1065438C (zh) 环状粘着抑制剂
CN1026064C (zh) 活性氧抑制组合物的制造方法
CN1054040C (zh) 载有喹诺酮羧酸衍生物的离子交换树酯的制备
CN1117874A (zh) 经鼻给药组合物
CN86100757A (zh) 改进或有关增加动物饲料摄取量的方法
CN86106150A (zh) 可嚼胶囊
CN86105023A (zh) 延长生长促进激素的释放
JP5477997B2 (ja) ビタミンｄ化合物の使用
CN105999231B (zh) 一种多肽组合物、提高畜禽免疫功能的组合物、制备方法
JP2007507213A5 (ru)
CN1041107A (zh) 促进猪生长的方法
JPS6089488A (ja) 新規アミノ酸誘導体の製法
CN1341591A (zh) 四水合n－[邻－(对－三甲基乙酰氧基苯磺酰胺基)苯甲酰基]甘氨酸单钠盐的溶液及其药品
CN1566086A (zh) 一种氨基酸螯合钙及其制剂和应用
CN106539822A (zh) 氟苯尼考粉及其制备方法
CN1129452C (zh) 表皮生长因子口含片
JPH0651628B2 (ja) 栄養剤組成物
CN112472714B (zh) 一种含硝酸盐的组合物及其应用
CN1264552C (zh) 一种预防骨质疏松和延缓衰老的制剂及其制备方法
RU2294196C2 (ru) Лечебно-кормовая добавка и способ ее применения при паразитозах животных
CN1171594C (zh) 含珍珠粉和抗坏血酸的组合物
RU2067445C1 (ru) Препарат "полифар" для лечения желудочно-кишечных болезней новорожденных телят
RU2185836C2 (ru) Витаминный препарат "апилактин"
RU2096970C1 (ru) Премикс для свиней "айболит"